Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Targeted Resequencing of 30 Genes Improves the Detection of Deleterious Mutations in South Indian Women with Breast and/or Ovarian Cancers

  • Published : 2015.08.03
Download PDF
⟨ Previous Next ⟩

Abstract

Background: We earlier used PCR-dHPLC for mutation analysis of BRCA1 and BRCA2. In this article we report application of targeted resequencing of 30 genes involved in hereditary cancers. Materials and Methods: A total of 91 patient samples were analysed using a panel of 30 genes in the Illumina HiScan SQ system. CLCBio was used for mapping reads to the reference sequences as well as for quality-based variant detection. All the deleterious mutations were then reconfirmed using Sanger sequencing. Kaplan Meier analysis was conducted to assess the effect of deleterious mutations on disease free and overall survival. Results: Seventy four of the 91 samples had been run earlier using the PCR-dHPLC and no deleterious mutations had been detected while 17 samples were tested for the first time. A total of 24 deleterious mutations were detected, 11 in BRCA1, 4 in BRCA2, 5 in p53, one each in RAD50, RAD52, ATM and TP53BP1. Some 19 deleterious mutations were seen in patients who had been tested earlier with PCR-dHPLC [19/74] and 5/17 in the samples tested for the first time, Together with our earlier detected 21 deleterious mutations in BRCA1 and BRCA2, we now had 45 mutations in 44 patients. BRCA1c.68_69delAG;p.Glu23ValfsX16 mutation was the most common, seen in 10/44 patients. Kaplan Meier survival analysis did not show any difference in disease free and overall survival in the patients with and without deleterious mutations. Conclusions: The NGS platform is more sensitive and cost effective in detecting mutations in genes involved in hereditary breast and/or ovarian cancers.

Keywords

References

  1. Bar-Sade RB, Kruglikova A, Modan B, et al (1998). The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazim. Hum Mol Genet, 7, 801-5. https://doi.org/10.1093/hmg/7.5.801
  2. Bell DW, Wahrer DC, Kang DH, et al (1999). Common nonsense mutations in RAD52. Cancer Res, 59, 3883-8.
  3. Bogdanova N, Feshchenko S, Schurmann P, et al (2008). Nijimegen breakage syndrome mutations and breast cancer. Int J Cancer, 122, 802-806. https://doi.org/10.1002/ijc.23168
  4. Braggio E, Egan JB, Fonseca R, Stewart AK (2013). Lessons from next-generation sequencing analysis in haematological malignancies. Blood Cancer J, [Epub ahead of print].
  5. Cao YW, Fu XG, Wan GX, et al (2014). BRCA1 gene exon 11 mutations in Uighur and Han women with early-onset sporadic breast cancer in the northwest region of China. Asian Pac J Cancer Prev, 15, 4513-8. https://doi.org/10.7314/APJCP.2014.15.11.4513
  6. Cox A, Dunning AM, Garcia-Closas M, et al (2007). Breast cancer association consortium. a common coding variant in CASP8 is associated with breast cancer risk. Nat Genet, 39, 352-8. https://doi.org/10.1038/ng1981
  7. De la Torre C, Pincheira J, Lopez-Saez JF (2003). Human syndromes with genomic instability and multiprotein machines that repair DNA double-strand break. Histol Histopathol, 18, 225-43.
  8. Easton DF, Pooley KA, Dunning AM, et al (2007). Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-93. https://doi.org/10.1038/nature05887
  9. Ferlay J, Soerjomataram I, Ervik M, et al (2013). Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: international agency for research on cancer. GLOBOCAN 2012 v1.0 . Available from: http://globocan.iarc.fr
  10. Han J, Hankinson SE, De Vivo I, Colditz GA, Hunter DJ (2002). No association between a stop codon polymorphism in RAD52 and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 11, 1138-9.
  11. Hearle N, Schumacher V, Menko FH, et al (2006). Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res, 12, 3209-15. https://doi.org/10.1158/1078-0432.CCR-06-0083
  12. Kooshyar MM, Nassiri M, Mahdavi M, Doosti M, Parizadeh A (2013). Identification of germline BRCA1 mutations among breast cancer families in northeastern Iran. Asian Pac J Cancer Prev, 14, 4339-45. https://doi.org/10.7314/APJCP.2013.14.7.4339
  13. Laudico A, Redaniel MT, Mirasol-Lumague MR, et al (2009). Epidemiology and clinicopathology of breast cancer in metro Manilla and Rizal province, Philippines. Asian Pac J Cancer Prev, 10, 167-72.
  14. Lee JH, Mand MR, Deshpande RA, et al (2013). Ataxia telangiectasia-mutated (ATM) is regulated byATP-driven conformational changes in the mre11/Rad50/Nbs1 (MRN) complex. J Biol Chem, 288, 12840-51. https://doi.org/10.1074/jbc.M113.460378
  15. Luo H, Li Z, Qing Y, et al (2014). Single nucleotide polymorphisms of DNA base-excision repair genes (APE1, OGG1 and XRCC1) associated with breast cancer risk in a Chinese population. Asian Pac J Cancer Prev, 15, 1133-40. https://doi.org/10.7314/APJCP.2014.15.3.1133
  16. Mahdi KM, Nassiri MR, Nasiri K (2013). Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14, 3403-9. https://doi.org/10.7314/APJCP.2013.14.6.3403
  17. Majeed W, Aslam B, Javed I, et al (2014). Breast cancer: major risk factors and recent developments in treatment. Asian Pac J Cancer Prev, 15, 3353-8. https://doi.org/10.7314/APJCP.2014.15.8.3353
  18. Masciari S, Larsson N, Senz J, et al (2007). Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet, 44, 7.
  19. Meldrum C, Doyle MA, Tothill RW (2011). Next generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev, 32, 177-95.
  20. Nichols KE1, Malkin D, Garber JE, Fraumeni JF Jr, Li FP (2001). Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev, 10, 83-7.
  21. Park MS, Ludwig DL, Stigger E, Lee SH (1996). Physical interaction between human RAD52 and RPA is required for homologous recombination in mammalian cells. J Biol Chem, 271, 18996-9000. https://doi.org/10.1074/jbc.271.31.18996
  22. Petitjean A, Mathe E, Kato S, et al (2007). Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat, 28, 622-9. https://doi.org/10.1002/humu.20495
  23. Rajkumar T, Soumittra N, Nancy NK, et al (2003). BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. Asian Pac J Cancer Prev, 4, 203-8.
  24. Ripperger T, Gadzicki D, Meindl A, Schlegelberger B (2009). Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet, 17, 722-31. https://doi.org/10.1038/ejhg.2008.212
  25. Saal LH, Gruvberger-Saal SK, Persson C, et al (2008). Recurrent gross mutations of the PTEN tumour suppressor gene in breast cancers with deficient DSB repair. Nat Genet, 40, 102-7. https://doi.org/10.1038/ng.2007.39
  26. Samson M, Swaminathan R, Rama R, et al (2007). Role of GSTM1 (Null/Present), GSTP1 (Ile105Val) and P53 (Arg72Pro) genetic polymorphisms and the risk of breast cancer-a case control study from South India. Asian Pac J Cancer Prev, 8, 253-7.
  27. Samson M, Swaminathan R, Rama R, et al (2009). CYP17 (T-34C), CYP19 (Trp39Arg), and FGFR2 (C-906T) polymorphisms and the risk of breast cancer in South Indian women population. Asian Pac J Cancer Prev, 10, 111-4.
  28. Schrader KA, Masciari S, Boyd N, et al (2008). Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer, 7, 73-82. https://doi.org/10.1007/s10689-007-9172-6
  29. Scott RJ, McPhillips M, Meldrum CJ, et al (2001). Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutationnegative kindreds. Am J Hum Genet, 68, 118-27. https://doi.org/10.1086/316942
  30. Sharma S, Sambyal V, Guleria K, et al (2014). P53 polymorphisms in sporadic North Indian breast cancer patients. Asian Pac J Cancer Prev, 15, 6871-9. https://doi.org/10.7314/APJCP.2014.15.16.6871
  31. Shin A, Lee KM, Ahn B, et al (2008). Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. Asian Pac J Cancer Prev, 9, 501-5.
  32. Soumittra N, Meenakumari B, Parija T, et al (2009). Molecular genetics analysis of hereditary breast and ovarian cancer patients in India. Hered Cancer Clin Pract, 7, 13. https://doi.org/10.1186/1897-4287-7-13
  33. Tinat J, Bougeard G, Baert-Desurmont S, et al (2009). 2009 version of the Chompret criteria for Li Fraumeni syndrome. JCO, 27, 108-9. https://doi.org/10.1200/JCO.2009.22.7967
  34. Tong D, Volm T, Eberhardt E, et al (2003). Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. Oncol Rep, 10, 1551-3.
  35. Vasen HF, Morreau H, Nortier JW (2001). Is breast cancer part of the tumour spectrum of hereditary nonpolyposis colorectal cancer? Am J Hum Genet, 68, 1533-5. https://doi.org/10.1086/320610
  36. Vaidyanathan K, Lakhotia S, Ravishankar HM, et al (2009). BRCA1 and BRCA2 germline mutation analysis among Indian women from south India: identi.cation of four novel mutations and high-frequency occurrence of 185delAG mutation. J Biosci, 34, 415-22. https://doi.org/10.1007/s12038-009-0048-9
  37. Walsh T, Lee MK, Casadei S, et al (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A, 107, 12629-33. https://doi.org/10.1073/pnas.1007983107
  38. Yang Y, Zhang F, Wang Y, Liu SC (2012). CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls. Asian Pac J Cancer Prev, 13, 3501-5. https://doi.org/10.7314/APJCP.2012.13.7.3501

Cited by

  1. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels vol.12, pp.9, 2017, https://doi.org/10.1371/journal.pone.0185615
  2. Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population vol.39, pp.2, 2017, https://doi.org/10.1177/1010428317694303
  3. pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome pp.10597794, 2018, https://doi.org/10.1002/humu.23656
  4. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations vol.170, pp.1, 2018, https://doi.org/10.1007/s10549-018-4726-x